RecruitingPhase 3NCT07177352
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition
Sponsor
Hoffmann-La Roche
Enrollment
13,000 participants
Start Date
Jul 2, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.
Eligibility
Min Age: 50 YearsMax Age: 90 Years
Inclusion Criteria1
- \- Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.
Exclusion Criteria5
- Dependency in basic activities of daily living (bADLs) due to cognitive impairment
- Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)
- Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD
- History of severe, clinically significant central nervous system trauma
- Any serious medical condition that precludes a participant's safe participation and completion of a clinical study
Interventions
OTHERNo Intervention
Participants will have their blood drawn and cognitive score measured by the ISLT.
Locations(207)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07177352
Related Trials
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150135 locations
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578120 locations
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
NCT064842441 location
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT0664749835 locations
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
NCT0555215735 locations